Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
UCB BIOSCIENCES GmbH
With
PPD Development, LP
This study consisted of:
* Induction Period (dosing at Weeks 0, 2, and 4)
* Maintenance Dosing (dosing every 4 weeks up to Week 260)
* End of Treatment Visit that occurred at Week 262/Withdrawal Visit and a Safety Follow-up Visit (SFU; 12 weeks after final dose)
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject participated in study C87085 \[NCT00552058\] in which the subject completed the study at Week 6
Subject is capable of providing informed consent, which must be obtained prior to any study related procedures
Have a chest X-ray taken at Visit 1 that is read by a qualified radiologist or pulmonary physician, with no evidence of current active Tuberculosis (TB) or old inactive TB
Subject has taken a TB survey and is committed to comply with TB prophylaxis if applicable
You may not be if
Subject is experiencing an ongoing serious adverse event assessed as being related to study medication or is experiencing a serious adverse event that is still not assessable
Subject has an intercurrent illness that requires termination of treatment, such as a serious infection (e.g. TB, pneumonia, sepsis, pyelonephritis, fistula abscess)
Subject is non-compliant with TB prophylactic treatment (if applicable)
Subject has had a chest X-ray at Visit 1 that shows an abnormality suggestive of a malignancy or active infection, including TB
Female who is pregnant or breast feeding
Female of child bearing age or post puberty males not practicing effective birth control
Subject is expecting to receive any live virus or bacterial vaccination within 3 months of first Study Medication administration, during the trial or 3 months after last dose of study drug
Clareo Health | A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease
